So far, omalizumab targeting IgE, mepolizumab targeting IL-5, reslizumab targeting IL-5 receptor and dupilumab targeting IL-4 have been licensed by American Food and Drug Administration (FDA) for treatment of asthma (Normansell et al. 2014; Pavord et al. 2012; Deeks and Brusselle 2017; Bacharier et al. 2021). This evidence concerns the gene IGHE and asthma.